Literature DB >> 9635846

Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.

J P Peyrat1, F Révillion, J Bonneterre.   

Abstract

Insulin-like growth factor 1 (IGF-1) plasma level was assayed in 60 breast cancer patients undergoing six courses of adjuvant chemotherapy. The only observed variation was a slight decrease (10%) in IGF-1 concentrations, assayed before treatment, between the first and the second courses of chemotherapy. During chemotherapy courses, there were no statistically significant variations in IGF-1. These results suggest that chemotherapy, unlike the specific hormonal treatments tamoxifen and somatostatin, certainly does not act via a decrease in plasma IGF-1.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9635846      PMCID： PMC2150068          DOI： 10.1038/bjc.1998.274

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  17 in total

1.  Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients.

Authors:  M Pollak; J Costantino; C Polychronakos; S A Blauer; H Guyda; C Redmond; B Fisher; R Margolese
Journal:  J Natl Cancer Inst       Date:  1990-11-07       Impact factor: 13.506

2.  Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I.

Authors:  M N Pollak; C Polychronakos; H Guyda
Journal:  Anticancer Res       Date:  1989 Jul-Aug       Impact factor: 2.480

3.  Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.

Authors:  S E Dunn; R A Hardman; F W Kari; J C Barrett
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

4.  Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.

Authors:  A Manni; A E Boucher; L M Demers; H A Harvey; A Lipton; M A Simmonds; M Bartholomew
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

5.  Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer.

Authors:  P Vennin; J P Peyrat; J Bonneterre; M M Louchez; A G Harris; A Demaille
Journal:  Anticancer Res       Date:  1989 Jan-Feb       Impact factor: 2.480

Review 6.  Pathophysiological and clinical aspects of the insulin-like growth factors.

Authors:  J Zapf; E R Froesch
Journal:  Horm Res       Date:  1986

7.  Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients.

Authors:  P E Lønning; K Hall; A Aakvaag; E A Lien
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

8.  The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer.

Authors:  M J Reed; A Christodoulides; R Koistinen; M Seppälä; J D Teale; M W Ghilchik
Journal:  Int J Cancer       Date:  1992-09-09       Impact factor: 7.396

Review 9.  Type 1 IGF receptor in human breast diseases.

Authors:  J P Peyrat; J Bonneterre
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

10.  Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer.

Authors:  D Yee; S Paik; G S Lebovic; R R Marcus; R E Favoni; K J Cullen; M E Lippman; N Rosen
Journal:  Mol Endocrinol       Date:  1989-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.